The Role of the Hinge Region of the Luteinizing Hormone Receptor in Hormone Interaction and Signal Generation*

Huawei ZengDagger , Tzulip PhangDagger , Yong Sang SongDagger §, Inhae JiDagger , and Tae H. JiDagger

From the Dagger  Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506-0055 and the § Cancer Research Center, Seoul National University College of Medicine, Seoul 110-744, Korea

Received for publication, August 16, 2000, and in revised form, August 28, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Luteinizing hormone receptor, a G protein-coupled receptor, consists of two halves, the N-terminal extracellular hormone binding domain (exodomain) and the C-terminal membrane-associated, signal-generating domain (endodomain). The exodomain has seven to nine Leu-rich repeats, which are generally thought to form a 1/3 donut-like structure and interact with human choriogonadotropin (hCG). The resulting hCG-exodomain complex adjusts the structure and its association with the endodomain, which results in signal generation in the endodomain. It is unclear whether the rigid 1/3 donut structure could provide the agility and versatility of this dynamic action. In addition, there is no clue as to where the endodomain contact point (the signal modulator) in the exodomain is. To address these issues, the exodomain was examined by Ala scan and multiple substitutions, while receptor peptides were used for photoaffinity labeling and affinity cross-linking. Our results show that the C-flanking sequence (hinge region), Thr250-Gln268, of the Leu-rich repeats (LRRs) specifically interacts with hCG, preferentially hCGalpha . This interaction is inhibited by exoloop 2 of the endodomain but not by exoloops 1 and 3, suggesting an intimate relationship between Thr250-Gln268, exoloop 2, and hCG. Taken together, our observations in this article suggest a new paradigm that the LRRs contact the front of hCG, while both flanking regions of the LRRs interact with the sides of hCG. This would trap hCG in the 1/3 donut structure of the LRRs and enhance the binding affinity. In addition, mutations of conserved Ser255 in the sequence can constitutively activate the receptor. This provides a clue for the signal modulator in the exodomain. In contrast, a phenyl or phenolic group is necessary at conserved Tyr253 for targeting the receptor to the surface.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The glycoprotein hormone receptors comprise two equal halves; an extracellular N-terminal half (exodomain) and a membrane-associated C-terminal half (endodomain). The exodomain is ~350 amino acids long, which alone is capable of high affinity hormone binding (1-3) without hormone action (3, 4). The endodomain consists of seven transmembrane domains, three exoloops, three cytoloops, a C-terminal tail, and a short extracellular extension connected to transmembrane domain 1. Receptor activation occurs in the endodomain (3, 5, 6), which is structurally equivalent to the entire molecule of many other G protein-coupled receptors (7). Existing data suggest that these two domains are associated together before and after hormone binding (8, 9). A hormone initially binds to the exodomain, and the resulting hormone-exodomain complex adjusts its conformation (10) and then interacts with the endodomain (7). This change in the interaction in the ternary complex, hCG-exodomain-endodomain, is thought to generate a signal (6, 7, 11).

There is ample evidence that the exodomain of the luteinizing hormone/choriogonadotropin receptor (LH/CG-R)1 alone is capable of binding hCG with high affinity. The truncated exodomain lacking the endodomain binds hCG with a high affinity similar to or slightly better than the wild type affinity (1-3). Exodomain fusion proteins are capable of binding hCG with a high affinity (12, 13). A number of sites in the exodomain are important for hormone binding (14-16) and hormone specificity (17-19). LHR peptides corresponding to three regions in the exodomain are capable of inhibiting hCG binding to the receptor (20).

A major feature in the structure of the LHR exodomain is the Leu-rich repeat (LRR) motif (21, 22). LRRs are found in a large number of proteins (23). The existing crystal structures of a few LRR proteins show up to 15 LRRs, which form a rigid 2/3 donut structure (24, 25). Based on these LRR crystal structures, the glycoprotein hormone receptors have been modeled (26-28). They show a 1/3 donut structure consisting of 7-9 LRRs and suggest that the inner lining interacts (16, 29, 30) with the concave, front side of the hormones (31, 32). Recently, it has been shown that the putative LRRs in the gonadotropin receptors are indeed active and that part of them interact with hCG (33-35).

However, it is unclear whether the rigid 1/3 donut structure of the LRRs alone interacts with hCG, adjusts its conformation, contacts with the endodomain, and activates the endodomain or if other regions of the exodomain are involved in the process. This agility and versatility may come from regions other than the LRRs. For example, we have shown that the N-terminal flanking region of the LRRs makes strong contact with both subunits of hCG (36, 37). However, it is unknown whether the N-terminal flanking region of the LRRs is the only exodomain region outside of the LRRs to interact with hCG. In addition to the insufficient knowledge on the exodomain/hCG interaction, little is known about the contact sites between the exodomain and endodomain. There is evidence that exoloops 2 and 3 of the endodomain are involved in the interaction with unliganded exodomain and constrain the hormone binding at the exodomain (8, 9). It has just been reported that LRR4 (34, 35) and the C-terminal flanking (hinge) region of the LRRs (38) modulate signal generation in the endodomain. However, there is no clue to where the endodomain contact point is in the exodomain. In this article, the first evidence is presented that the hinge region interacts with hCG and that the hCG-exodomain complex makes contacts with exoloop 2 of the endodomain.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- The N-hydroxysuccinimide of 4-azidobenzoic acid (NHS-AB) was synthesized as described previously (39). The N-hydroxysulfosuccinimide esters of ethylene glycolbis(sulfosuccinimidylsuccinate) (SES) were purchased from Pierce. The hCG CR 127 and hCG subunits were supplied by the National Hormone and Pituitary Program. Denatured hCG was prepared by boiling hCG in 8 M urea for 30 min. Receptor peptides were synthesized and N-acetylated and C-amidated by Biosynthesis (Lewisville, TX). They were purified on a Vydac C18 high performance liquid chromatography column using a solvent gradient from 100% of 0.1% trifluoroacetic acid in water to 20% of 0.1% trifluoroacetic acid in water and 80% 1-propanol.

Mutagenesis and Functional Expression of LHR-- Mutant LHR cDNAs were prepared in a pSELECT vector using the Altered Sites Mutagenesis System (Promega), sequenced, subcloned into pcDNA3 (Invitrogen) as described previously (40), and sequenced again to verify mutation sequences. This procedure does not involve polymerase chain reaction, and therefore, there are no polymerase chain reaction-associated unintended mutations. To produce truncated receptors, a codon was substituted with a stop codon. Mutant and truncated LHR constructs were transfected into human embryonic kidney 293 cells by the calcium phosphate method. Stable cell lines were established in minimum essential medium containing 10% horse serum and 500 µg/ml of G-418. They were used for hormone binding and cAMP production. All assays were carried out in duplicate and repeated four to six times. Means and standard variations were calculated.

125I-hCG Binding and Intracellular cAMP Assay-- Stable cells were assayed for 125I-hCG binding in the presence of a constant amount of 125I-hCG (39) and increasing concentrations of unlabeled hCG. The Kd values were determined by Scatchard plots. For intracellular cAMP assay, cells were washed twice with Dulbecco's modified Eagle's medium and incubated in the medium containing isobutylmethylxanthine (0.1 µg/ml) for 15 min. Increasing concentrations of hCG were then added, and the incubation was continued for 45 min at 37 °C. After removing the medium, the cells were rinsed once with fresh medium without isobutylmethylxanthine, lysed in 70% ethanol, freeze-thawed in liquid nitrogen, and scraped. After pelleting cell debris at 16,000 × g for 10 min at 4 °C, the supernatant was collected, dried under vacuum, and resuspended in 10 µl of the cAMP assay buffer, which was provided by Amersham Pharmacia Biotech. cAMP concentrations were determined with an 125I-cAMP assay kit (Amersham Pharmacia Biotech) following the manufacturer's instruction and validated for use in our laboratory. All assays for cAMP and binding to intact cells and solubilized receptors were repeated four to six times in duplicate to calculate means ± S.D.

125I-hCG Binding to Solubilized LHR-- Transfected cells were washed twice with ice-cold 150 mM NaCl, 20 mM HEPES, pH 7.4 (buffer A). Cells were scraped on ice and collected in buffer A containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 5 mM N-ethylmaleimide, and 10 mM EDTA) and pelleted by centrifugation at 1,300 × g for 10 min. Cells from a 10 cm plate were resuspended in 0.6 ml of buffer A containing 1% Nonidet P-40, 20% glycerol, and the above protease inhibitors (buffer B), incubated on ice for 15 min, and diluted with 5.4 ml of buffer A containing 20% glycerol plus the protease inhibitors (buffer C). The mixture was centrifuged at 100,000 × g for 60 min. The supernatant (500 µl) was mixed with 150,000 cpm of 125I-hCG and 6.5 µl of 0.9% NaCl and 10 mM Na2HPO4 at pH 7.4 containing increasing concentrations of unlabeled hCG. after incubation at 4 °C for 12 h, the solution was thoroughly mixed with 250 µl of buffer A containing bovine gamma -globulin (5 µg/ml) and 750 µl of buffer A containing 20% polyethylene glycol 8000. After incubation at 4 °C for 10 min, samples were pelleted at 1300 × g for 30 min and supernatants removed. Pellets were resuspended in 1.5 ml of buffer A containing 20% polyethylene glycol 8000, centrifuged, and counted for radioactivity.

Derivatization and Radioiodination of Peptide-- NHS-AB was freshly dissolved in dimethyl sulfoxide to a concentration of 50 mM in 0.1 M sodium phosphate, pH 7.5, to a concentration of 20 mM. This reagent solution was immediately used to derivatize receptor peptides. In the dark, 10 µl of NHS-AB was added to 30 µg of LHR246-269 in 40 µl of 0.1 M sodium phosphate, pH 7.5. The mixture was incubated for 30 min for NHS-AB or 60 min for NHS-AB at 25 °C. The following were added to the derivatization mixture: 1 mCi of Na125I in 10 µl of 0.1 M NaOH and 7 µl of chloramine T (1 mg/ml) in 10 mM Na2HPO4 and 0.9% NaCl, pH 7.4 (PBS). After 20 s, 7 µl of sodium metabisulfite (2.5 mg/ml) in PBS was introduced to terminate radioiodination. Derivatized and radioiodinated AB-125I-LHR246-269 solution was mixed with 60 µl of 16% sucrose solution in PBS and fractionated on Sephadex Superfine G-10 column (0.6 × 15 cm) using PBS.

Affinity Cross-linking of 125I-LHR246-269 to hCG-- Disposable glass tubes were siliconized under dimethyldichlorosilane vapor overnight and autoclaved. In each siliconized tube, 20 µl of PBS, hCG (70 ng in 10 µl of PBS), and 125I-LHR246-269 (100 ng in 10 µl of PBS) were mixed and incubated in 37 °C for 90 min. After incubation, 3 µl of 0.1 mM SES in dimethyl sulfoxide was added to each tube and further incubated at 25 °C for 20 min. The cross-linking reaction was terminated by adding 3 µl of 5 mM Gly in PBS. The samples were boiled for 2 min in 2% sodium dodecyl sulfate, 100 mM dithiothreitol, and 8 M urea. The solubilized samples were electrophoresed on 8-12% polyacrylamide gradient gels. Gels were dried on filter paper, then exposed to a molecular imaging screen (Bio-Rad) overnight. The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad), and radioactive band intensity was analyzed using Image Analysis Systems Version 2.1 (Bio-Rad). Gels were exposed to X-Omat x-ray film at -75 °C for ~4 days

Photoaffinity Labeling of hCG-- The following solutions were sequentially introduced to siliconized glass tubes: 20 µl of PBS, 10 µl of hCG (10 ng/µl) in PBS, and 10 µl of AB-125I-LHR246-269 (10 ng/µl) in PBS. The mixtures were incubated at 37 °C for 90 min in the dark, irradiated with Mineralight R-52 UV lamp for 3 min as described previously (41), and solubilized in 2% SDS, 100 mM dithiothreitol, and 8 M urea. The samples were electrophoresed on 8-12% polyacrylamide gradient gels. Gels were dried on filter paper and processed as described above.

Competitive Inhibition of Affinity Labeling of hCG and Inhibition of 125I-hCG Binding to LHR-- Competitive inhibition experiments were carried out as described for the affinity cross-linking and photoaffinity labeling experiments, except that 10 µl instead of 20 µl of PBS was introduced to each tube, and the mixture was incubated with 10 µl of increasing concentrations of nonradioactive wild type or mutant LHR246-269.

A human embryonic kidney 293 cell line stably expressing human LHR was incubated with 100,000 cpm of 125I-hCG in the presence of increasing concentrations of nonradioactive wild type or mutant LHR246-269 as described previously (42). After washing the cells several times, the radioactivity associated with the cells was counted to determine the Kd value.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Truncation of the C Terminus-- LHR is encoded by 11 exons (22, 43), and the exodomain is primarily comprised of exons 1-10, whereas the endodomain is mainly encoded in exon 11. When exons 1-10 were expressed in mammalian cells after truncating exon 11, the exodomain fragment was trapped within the cells and could not be detected on the intact cell surface or in the culture medium (2, 3). However, when the cells were solubilized in nonionic detergent, the exodomain fragment was capable of binding hCG with a high affinity similar to the hormone binding affinity of the wild type receptor (Table I) as reported previously (1-3). When the terminal region was further truncated by deleting both exons 10 and 11, the resulting exodomain fragment consisting of exons 1-9 was also trapped in cells and capable of hormone binding. The binding affinity was, however, significantly less as the Kd value was ~6-fold greater than that of the wild type receptor in detergent solution (Table I). This result suggests the presence of a potentially important site around the exon 9-10 boundary (36).


                              
View this table:
[in this window]
[in a new window]
 
Table I
Hormone binding of LHR
The wild type LHR and exodomain fragment comprised of exons 1-10 or exons 1-9 were stably expressed in 293 cells and assayed for hCG binding to intact cells and receptors solubilized in Nonidet P-40. NS stands for not significant.

Sequence Comparison and Ala Scan of Conserved Residues-- To screen important residues in the exon 9-10 junction of LHR, the junction sequence was aligned with the corresponding sequence of the FSH receptor and TSH receptor (Fig. 1). A homology sequence was found from Tyr253 to Phe260. In addition, the sequence corresponding to LHR Arg261-Gln268 is highly conserved within each receptor type among species. We decided to Ala scan from Thr250 to Gln268 except Ala259 that was substituted with Gly. The resulting mutant receptors were stably expressed in cells and intact cells were assayed for 125I-hCG binding and cAMP induction (Fig. 2). In addition, cells that were unable to bind hormone were solubilized in Nonidet P-40 and assayed for 125I-hCG binding in solution.



View larger version (82K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment. The amino acid sequence around the exon 9-10 junction is aligned for the LH, FSH, and TSH receptors. "*" represents a conserved residue.



View larger version (56K):
[in this window]
[in a new window]
 
Fig. 2.   Ala scan of Thr250-Gln268. Residues in the Thr250-Gln268 sequence were individually substituted with Ala, except the Ala259 right-arrow Gly substitution. The resulting mutants were stably expressed in 293 cells and assayed for hCG binding to intact cells and cAMP induction as described under "Experimental Procedures." Nonbinding cells were solubilized in Nonidet P-40 and assayed for hCG binding. Each experiment was repeated four to six times in duplicate and means ± S.D. were calculated. NS stands for not significant.

The results reveal two mutant classes: one that was capable of binding hCG on intact cells and the other incapable of hCG binding on intact cells. All of the latter were capable of binding hCG after solubilization in Nonidet P-40, indicating that Ala substitutions did not abolish the hCG binding activity and that the mutants were trapped in cells (36). The Kd values were generally higher than the wild type value except Cys257 right-arrow Ala and Phe260 right-arrow Ala, indicating lower affinities. The lower affinities do not appear to be due to the variations in the receptor concentration, because they are in the range of 22,000-57,000/cell, except for Thr252 right-arrow Ala and Phe260 right-arrow Ala. At these concentrations, the receptors show normal activities (9, 33, 34, 44). It is interesting to note that all mutants in the second half of the sequence from Ala259 right-arrow Gly to Gln268 right-arrow Ala were expressed on the surface, whereas only four mutants from Thr250 to Cys258 were expressed on the surface. This result suggests that the first half, but not the second half, of the sequence may be important for receptor targeting to the cell surface.

Substitutions for Tyr253 Impair Surface Expression-- To further investigate the impact on surface expression, Tyr253 was substituted with an array of amino acids (Table II). The substitution of Phe did not impact the surface expression or the surface receptor concentration. In contrast, the His substitution significantly impaired the surface expression, and other substitutions blocked it. These results show that Tyr253 right-arrow Phe and a phenyl group at the Tyr253 position are permissible for receptor targeting and hormone binding. Therefore, the hydroxyl moiety of the Tyr's phenolic group does not appear to influence the targeting and hormone binding. The partial blockage of surface expression by the substitution of His suggests that an imidazole at the Tyr253 position is tolerable but not desirable. Substitutions of nonaromatic hydrophobic, hydrophilic, neutral, and acidic amino acids for Tyr253 prevented surface expression of the receptor, although the concentration of the mutant receptors trapped in cells was significant and sometimes considerably higher than the total concentration of the wild type receptor. These results suggest that a phenolic or phenyl group is necessary at the Tyr253 position for efficient receptor transport to the surface membrane. To test this possibility and the essential role of Tyr253, the residue was deleted. The resulting Tyr253 deletion mutant was not expressed on the surface, supporting the hypothesis.


                              
View this table:
[in this window]
[in a new window]
 
Table II
Multiple substitutions for Tyr253
Tyr253 was substituted with an array of amino acids. Del stands for deletion. The mutant receptors were expressed and assayed for hCG binding to intact cells and in solution as well as cAMP induction as described under "Experimental Procedures." NS stands for not significant.

One may argue that cells expressing trapped receptors might have developed a defective mechanism for receptor transport, perhaps when stable cell lines were being established. To test this unlikely possibility, the cells stably expressing the Tyr253 right-arrow Ala mutant were transfected again with the wild type LH/CG-R or the human FSH receptor plasmid (45). The transfected cells were capable of binding hCG or FSH, respectively (Table III), indicating that the receptor transport mechanism was functional. To exclude the possibility that the second transfection rescued the receptor transport mechanism, additional experiments were performed. Cells stably transfected with the FSH receptor or wild type LH receptor were transfected again with the Tyr253 right-arrow Ala mutant plasmid. These doubly transfected intact cells were capable of binding FSH or hCG, respectively, indicating that the receptor-targeting mechanism was not affected by transfection of the Tyr253 right-arrow Ala mutant plasmid and expression of the Tyr253 right-arrow Ala mutant.


                              
View this table:
[in this window]
[in a new window]
 
Table III
Activities of cotransfected receptors
Cells that were stably expressing the Tyr253 right-arrow Ala mutant receptor in cells were transiently transfected with the wild type LHR or wild type FSH receptor plasmid. The cells were assayed for hormone (hCG or FSH) binding as described under "Experimental Procedures." Conversely, cells that were stably expressing the FSH receptor on the cell surface were transiently transfected with the Tyr253 right-arrow Ala mutant receptor plasmid and assayed for hormone binding. NS stands for not significant; WT indicates wild type.

Constitutive Activation of cAMP Induction by Substitution for Ser255-- The examination of cAMP induction discloses that the mutations impaired the EC50 value, maximum level, or both for cAMP induction (Fig. 2, A and B). The only exception is Ser255 right-arrow Ala. It showed a similar EC50 and higher maximum cAMP as compared with the wild type values, suggesting an improved efficacy of cAMP induction. To follow up this interesting observation, Ser255 was replaced with several amino acids (Table IV). The resulting mutants were transiently surface-expressed in the ~20,000-40,000/cell range. Some of mutations, Val and Ile, resulted in strikingly high basal cAMP levels, despite lower receptor concentrations on the surface. This is unusual because all activating mutations uncovered to date are found in the endodomain (11, 46). A simple explanation is that the region may be involved in signal generation in the endodomain. If so, it may interact with hCG, the endodomain, or both. However, it is also possible that the mutations might have impacted protein processing including folding and thus, the global structure, which in turn resulted in the observed high basal cAMP level. One way to resolve this difficult issue is to determine its interaction, which can be done by affinity labeling.


                              
View this table:
[in this window]
[in a new window]
 
Table IV
Multiple substitutions for Ser255
Ser255 was substituted with several amino acids. The mutant receptors were expressed and assayed for hCG binding to intact cells and in solution as well as cAMP induction as described under "Experimental Procedures."

Affinity Labeling of hCG with Receptor Peptide LHR-- We synthesized a 24-mer peptide, Ac-Leu246-Asn269-NH2 (LHR246-269), derivatized it with NHS-AB, and radioiodinated it to produce AB-125I-LHR246-269. NHS-AB couples to the Lys residues, and Lys265 and Lys266 are present in the peptide. To determine whether AB-125I-LHR246-269 would bind and label hCG, and if so, which subunit is labeled, the peptide derivative was incubated with hCG and irradiated with UV for increasing time periods (Fig. 3A). The samples were solubilized in SDS under reducing conditions and electrophoresed as described under "Experimental Procedures." The autoradiographic phosphoimage of the gel shows that AB-125I-LHR246-269 labeled conspicuously both the alpha  and beta  subunits in hCG as well as faintly the alpha beta dimer. The positions of hCGalpha , hCGbeta , and the hCGalpha beta dimer were determined by comparing the respective positions of 125I-hCGalpha , 125I-hCGbeta , and the cross-linked 125I-hCG alpha beta dimer on the autoradiograph (35, 37). The labeling was dependent on UV irradiation, reaching the maximum level at 60-s exposure. The labeling of the alpha beta dimer implies that there were two AB groups attached to the peptide and that one was apparently closer to hCGalpha and labeled it, whereas the other was closer to and labeled hCGbeta . This is in contrast to an LHR peptide derivatized with an AB that is capable of labeling only one of the subunits but not both (35, 37). It suggests the specificity of photoaffinity labeling.



View larger version (46K):
[in this window]
[in a new window]
 
Fig. 3.   UV- and hCG-dependent photoaffinity labeling. AB-125I-LHR246-269 (200 ng) was incubated with 200 ng of hCG and irradiated with UV for varying time periods (A) or incubated with increasing concentrations of hCG and exposed to UV for 60 s (B). After electrophoresis of the samples, gels were dried on filter paper and exposed to a molecular imaging screen (Bio-Rad) overnight. The imaging screen was scanned on a model GS-525 Molecular Imager System Scanner (Bio-Rad), and the radioactive band intensity was analyzed using Image Analysis Systems Version 2.1 (Bio-Rad). Gels were also exposed to X-Omat x-ray film at -75 °C for ~4 days. The bar graphs show the percent radioactivity of the alpha  band and the beta  band in a gel lane.

Next, increasing concentrations of hCG were incubated with a constant amount of AB-125I-LHR246-269 and irradiated with UV for 60 s (Fig. 3B). The results show that the hCG labeling was also dependent on the hCG concentration, reaching a maximum labeling at and above 200 ng. In the following experiment, 200 ng of hCG was incubated with increasing concentrations of AB-125I-LHR246-269 and UV-photolyzed for 60 s (Fig. 4A). The result shows the dependence of the labeling on the AB-125I-LHR246-269 concentration with the maximum labeling at and above 200 ng of AB-125I-LHR246-269. This experiment, taken together with the UV- and hCG-dependent experiments, indicate that the labeling of hCGalpha , hCGbeta , and hCGalpha beta is saturable and requires the peptide derivative, hCG, and UV photolysis. In addition, the results indicate that hCG was covalently labeled by AB-125I-LHR246-269 and that this labeling was specific. To test whether the derivatization of AB impacted the activity of the peptide, AB-125I-LHR246-269 was incubated with hCG in the presence of increasing concentrations of nonlabeled peptide and photolyzed (Fig. 4B). Nonlabeled peptide competitively inhibited the labeling. To further test the labeling specificity, AB-125I-LHR246-269 was incubated with increasing concentrations of denatured hCG and photolyzed. No labeled bands appeared (data not included), indicating that AB-125I-LHR246-269 labeled active, but not denatured, hCG.



View larger version (42K):
[in this window]
[in a new window]
 
Fig. 4.   LHR peptide-dependent photoaffinity labeling. hCG (200 ng) was incubated with increasing concentrations of AB-125I-LHR246-269 and exposed to UV for 60 s (A). hCG (200 ng) was incubated with 200 ng of AB-125I-LHR246-269 in the presence of increasing concentrations of nonlabeled LHR246-269 and exposed to UV for 60 s (B). The bar graphs show the percent radioactivity of the alpha  band and the beta  band in a gel lane.

Affinity Cross-linking of 125I-LHR246-269 to hCG-- Despite the specificity of photoaffinity labeling, one may raise an issue whether the AB attached to the peptide, particularly those at the contact point, might have interfered with the binding and labeling and distorted the result. To resolve this issue, the peptide without attached AB, 125I-LHR246-269, was cross-linked to hCG using an amino-specific homobifunctional reagent, SES. The results (Figs. 5 and 6) show that the peptide was cross-linked to both hCG subunits and the hCGalpha beta dimer. The affinity cross-linking requires SES, 125I-LHR246-269, and hCG and is dependent on their concentrations. The maximum levels of cross-linking reached around 15% of total peptide for hCGalpha and 10% for hCGbeta , indicating that the labeling is saturable and specific. In addition, hCGalpha was preferentially labeled compared with hCG, which is consistent with the preferential photoaffinity labeling of the hCGalpha subunit. This affinity cross-linking is more effective than photoaffinity labeling. A possible explanation is that SES can reach further than AB can, because of the maximum cross-linkable distance, ~13 Å for SES and ~7 Å for AB. The SES cross-linking results also show that either or both amino groups of Lys265 and Lys266 of 125I-LHR246-269, the only amino groups in the peptide, were cross-linked to one of seven hCGalpha amines, five hCGbeta amines, or those in both subunits. The SES-dependent cross-linking of 125I-LHR246-269 to the hCG subunits was competitively inhibited by nonlabeled peptide, suggesting a specificity. Furthermore, SES failed to cross-link 125I-LHR246-269 to denatured hCG (data not included).



View larger version (51K):
[in this window]
[in a new window]
 
Fig. 5.   SES- and hCG-dependent cross-linking of 125I-LHR246-269 to hCG. hCG was incubated with 125I-LHR246-269 and treated with SES for 15 min. Here, the concentration of SES (A) or hCG (B) was varied. The samples were electrophoresed, and gels were processed as described in the legend to Fig. 3. The bar graphs show the percent radioactivity of the alpha  band and the beta  band in a gel lane.



View larger version (48K):
[in this window]
[in a new window]
 
Fig. 6.   LHR peptide-dependent cross-linking of 125I-LHR246-269 to hCG. hCG (200 ng) was incubated with increasing concentrations of 125I-LHR246-269 and treated with 1 mM SES (A). hCG (200 ng) was incubated with 200 ng of 125I-LHR246-269 in the presence of increasing concentrations of nonlabeled LHR246-269 and treated with 1 mM SES (B). The samples were electrophoresed, and gels were processed as described in the legend to Fig. 3. The bar graphs show the percent radioactivity of the alpha  band and the beta  band in a gel lane.

Differential Effects of Exoloop Peptides on Photoaffinity Labeling of hCG-- Our mutational analysis suggests that the Thr250-Gln268 region may be involved in signal generation in the endodomain, perhaps interacting with hCG, the endodomain, or both. Such interactions, if true, might impact the specific affinity labeling of hCG with LHR246-269. To this end, hCG was incubated with AB-125I-LHR246-269 in the presence of an excess amount of exoloop peptides and irradiated with UV (Fig. 7A). The labeling was inhibited most conspicuously by the exoloop 2 peptide, whereas the inhibition by the exoloop 3 peptide or exoloop 1 peptide was significantly less or barely noticeable, respectively (Fig. 7, B and C).



View larger version (43K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of exoloop 1, 2, and 3 peptides on photoaffinity labeling of hCG by AB-125I-LHR246-269. hCG and AB-125I-LHR246-269 were incubated with 7,000 ng of nonlabeled LHR exoloop 1, 2, or 3 peptides and exposed to UV (A). hCG and AB-125I-LHR246-269 were incubated with increasing concentrations of nonlabeled LHR exoloop 1, 2, or 3 peptides and exposed to UV (B). The samples were electrophoresed, and gels were processed as described in the legend to Fig. 3. The graphs show the percent radioactivity of the alpha  band and the beta  band in a gel lane (C).



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The results of our mutagenesis and affinity labeling studies indicate that the Thr250-Gln268 sequence of the LHR exodomain interacts with both subunits of hCG, particularly with hCGalpha . In previous reports, we have shown that the LRRs function in the LHR exodomain and interact with hCG (33-35) and that the N-flanking region of the LRRs also interacts with hCG (36, 37). Receptor peptide mimics were useful in these studies, although synthetic peptide mimics have limitations. They do not necessarily mimic the function of the corresponding sequences in proteins, probably due to structural differences. This is underscored by the fact that an extension of either terminus or substitution of a single amino acid in peptides mimics deprives their activity, specificity, or both (20, 35, 37). Therefore, we have carefully chosen the sequence and size of the hinge peptide based on our mutational analysis and others' studies (20, 36). Furthermore, short synthetic peptides can be structured for a stable tertiary structure (47) and assume a potent biological activity (48-50).

Taken together, our observations show that the LRRs and their flanking regions interact with hCG. This suggests an intriguing possibility that the LRRs face hCG, probably at the front of hCG with the beta  seat belt and alpha  C terminus (31, 32), whereas the flanking regions of the LRRs face the sides of hCG and may reach the back of hCG. This would trap hCG in the 1/3 donut structure of the LRRs, slowing the dissociation rate of hCG and LHR (51) and enhancing the affinity. This is consistent with the fact that high affinities are generally ascribed to slow dissociation rates rather than fast association rates (52). For example, kinetic studies on interactions between hormones and receptors, antibodies and antigens, and enzymes and substrates show that association rate constants, kon, are in the narrow range of 105-107 M-1 s-1, whereas dissociation rate constants, koff, vary widely from 1 s-1 for low affinity complexes to a half-life of more than 3 months (10-7 s-1) (52).

An hCG contact point in the Thr250-Gln268 sequence is near or not too far from the two tandem Lys residues at 265 and 266 in the second half of the sequence. This is consistent with the fact that most Ala substitutions for the second half residues reduced the binding affinity by up to 2.3-fold but did not noticeably impact the surface expression and maximum cAMP induction level (Fig. 3, A and B). In contrast to this primary role of the second half in hCG binding, the first half of the sequence seems to be involved in the signal generation. For example, some substitutions for Ser255 resulted in substantially high basal cAMP levels. In particular, the cAMP level was dramatically high for Val and Ile substitutions, indicating constitutive activation of adenylyl cyclase (38). Taken together with the results that the interaction of the Thr250-Gln268 sequence with hCG is inhibited by the exoloop 2 peptide, our observations implicate the involvement of the Thr250-Gln268 sequence in the interaction of hCG-exodomain complex with the endodomain and the subsequent signal generation. This is the first clue to the identification of the endodomain contact points in the exodomain. The exoloop 2 peptide may directly compete with LHR246-269 for the binding site or allosterically interfere with the interaction between LHR246-269 and hCG. On the other hand, the exoloop 3 peptide marginally inhibited the labeling of hCG by AB-125I-LHR246-269, and the inhibition by the exoloop 1 peptide was barely detectable. This suggests several possibilities that these peptides bind hCG, but the affinities are relatively low, do not share the binding site of LHR246-269, or do not bind hCG at all. Since exoloop 3 impacts hCG binding to the exodomain, it is possible that exoloop 3 is capable of binding the exodomain or hCG-exodomain complex, but the affinity is low. In addition, exoloop 3 and the LHR246-269 sequence may not share a significant portion of their binding sites in hCG and the hCG-exodomain complex.

A phenyl or phenolic group at Tyr253 is crucial for the recognition by the surface-targeting machinery, since both Tyr and Phe are permissible. It is striking to see that substitutions of other amino acids, including other hydrophobic amino acids, completely blocked the surface expression, suggesting a high specificity. The attenuation of surface expression by Ala substitution for Leu251-Thr252-Tyr253 and His256-Cys257-Cys258 is specific, and therefore, these residues may assume a particular structure. The two groups consist of 3 contiguous amino acids, and a secondary structure analysis suggests interesting possibilities. The Leu251-Thr252-Tyr253 sequence is predicted to be part of a beta  sheet (53), thus orienting Leu251 and Tyr253 on one side of the beta  sheet and Thr252 on the other. In such a structure, Leu251 and Tyr253 face one side, whereas Thr252 would face the opposite side. This may explain why Leu251 and Tyr253 were more important for receptor transport than Thr252. Furthermore, it has been suggested that Leu and Tyr are part of a transport determinant of membrane proteins (54). Interestingly, the beta  sheet is followed by a turn at Pro254 and Ser255 (53, 55). Therefore, the two groups, Leu251-Thr252-Tyr253 and His256-Cys257-Cys258, are likely to be in close proximity, which could allow them to form a contiguous determinant. This is also consistent with the observation that Pro254 and Ser255 play a role distinct from the flanking residues, in particular the unique role in modulating signal generation (38).

In conclusion, the results presented in this study show that the C-terminal flanking (hinge) region (38), Thr250-Gln268, of the LRRs in the LHR exodomain interacts with hCG, contacting primarily hCGalpha . This interaction is specifically inhibited by exoloop 2 but not by exoloops 1 and 3 of the endodomain, suggesting an intimate relationship in the ternary complex of Thr250-Gln268, exoloop 2 and hCG. Taken together, our observations in this and previous articles (33-35) suggest a new paradigm that the LRRs face the front of hCG, while both of the flanking regions of the LRRs interact with the sides of hCG and possibly reach the back of hCG as well. This would trap hCG in the 1/3 donut structure of the LRRs, increasing the binding affinity. In addition, mutations of Ser255 in the exodomain sequence can constitutively activate the receptor. This result, along with the ternary complex, provides a new clue for the identity of the enigmatic signal modulator in the exodomain.


    FOOTNOTES

* This work was supported by Grants HD-18702 and DK-51469 from the National Institutes of Health.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom all correspondence should be addressed: Dept. of Chemistry, University of Kentucky, Lexington, KY 40506-0055. Tel.: 859-257-3163; Fax: 859-527-3229; E-mail: tji@pop.uky.edu.

Published, JBC Papers in Press, August 29, 2000, DOI 10.1074/jbc.M007488200


    ABBREVIATIONS

The abbreviations used are: LH, luteinizing hormone; CG, choriogonadotropin; CG-R, CG receptor; h, human; LHR, LH receptor; PBS, phosphate-buffered saline; NHS-AB, the N-hydroxysuccinimide of 4-azidobenzoic acid; SES, ethylene glycolbis(sulfosuccinimidylsuccinate); LRR, Leu-rich repeat; FSH, follicle-stimulating hormone; FSHR, FSH receptor; TSH, thyroid-stimulating hormone.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Tsai-Morris, C. H., Buczko, E., Wang, W., and Dufau, M. L. (1990) J. Biol. Chem. 265, 19385-19388[Abstract/Free Full Text]
2. Xie, Y. B., Wang, H., and Segaloff, D. L. (1990) J. Biol. Chem. 265, 21411-21414[Abstract/Free Full Text]
3. Ji, I., and Ji, T. H. (1991) Endocrinology 128, 2648-2650[Abstract]
4. Remy, J. J., Bozon, V., Couture, L., Goxe, B., Salesse, R., and Garnier, J. (1993) Biochem. Biophys. Res. Commun. 193, 1023-1030[CrossRef][Medline] [Order article via Infotrieve]
5. Ji, I., and Ji, T. H. (1991) J. Biol. Chem. 266, 13076-13079[Abstract/Free Full Text]
6. Ji, T. H., Murdoch, W. J., and Ji, I. (1995) Endocrine 3, 187-194
7. Ji, T. H., Grossmann, M., and Ji, I. (1998) J. Biol. Chem. 273, 17299-17302[Free Full Text]
8. Ryu, K., Lee, H., Kim, S., Beauchamp, J., Tung, C., Isaacs, N. W., Ji, I., and Ji, T. H. (1998) J. Biol. Chem. 273, 6285-6291[Abstract/Free Full Text]
9. Ryu, K., Gilchrist, R. L., Tung, C., Ji, I., and Ji, T. H. (1998) J. Biol. Chem. 273, 28953-28958[Abstract/Free Full Text]
10. Ji, I., Pan, Y.-N., Lee, Y.-M., Phang, T., and Ji, T. H. (1995) Endocrine 3, 907-911
11. Dufau, M. L. (1998) Annu. Rev. Physiol. 60, 461-496[CrossRef][Medline] [Order article via Infotrieve]
12. Osuga, Y., Kudo, M., Kaipia, A., Kobilka, B., and Hsueh, A. J. (1997) Mol. Endocrinol. 11, 1659-1668[Abstract/Free Full Text]
13. Lobel, L. I., Rausch, P., Trakht, I., Pollak, S., and Lustbader, J. W. (1997) Endocrinology 138, 1232-1239[Abstract/Free Full Text]
14. Bhowmick, N., Narayan, P., and Puett, D. (1999) Endocrinology 140, 4558-4563[Abstract/Free Full Text]
15. Zhang, R., Buczko, E., and Dufau, M. (1996) J. Biol. Chem. 271, 5755-5760[Abstract/Free Full Text]
16. Abell, A., Liu, X., and Segaloff, D. L. (1996) J. Biol. Chem. 271, 4518-4527[Abstract/Free Full Text]
17. Braun, T., Schofield, P. R., and Sprengel, R. (1991) EMBO J. 10, 1885-1890[Abstract]
18. Moyle, W. R., Campbell, R. K., Myers, R. V., Bernard, M. P., Han, Y., and Wang, X. (1994) Nature 368, 251-255[CrossRef][Medline] [Order article via Infotrieve]
19. Liu, X., DePasquale, J. A., Griswold, M. D., and Dias, J. A. (1994) Endocrinology 135, 682-691[Abstract]
20. Roche, P. C., Ryan, R. J., and McCormick, D. J. (1992) Endocrinology 131, 268-274[Abstract]
21. McFarland, K., Sprengel, R., Phillips, H., Kohler, M., Rosemblit, N., Nikolics, K., Segaloff, D., and Seeburg, P. (1989) Science 245, 494-499[Medline] [Order article via Infotrieve]
22. Koo, Y. B., Ji, I., Slaughter, R. G., and Ji, T. H. (1991) Endocrinology 128, 2297-2308[Abstract]
23. Kobe, B., and Deisenhofer, J. (1994) Trends Biochem. Sci. 19, 415-421[CrossRef][Medline] [Order article via Infotrieve]
24. Kobe, B., and Deisenhofer, J. (1995) Nature 374, 183-186[CrossRef][Medline] [Order article via Infotrieve]
25. Papageorgiou, A. C., Shapiro, R., and Acharya, K. R. (1997) EMBO J. 16, 5162-5177[Abstract/Free Full Text]
26. Jiang, X., Dreno, M., Buckler, D., Cheng, S., Ythier, A., Wu, H., Hendrickson, W., and Tayar, N. (1995) Structure (Lond.) 3, 1341-1353[Medline] [Order article via Infotrieve]
27. Bhowmick, N., Huang, J., Puett, D., Isaacs, N. W., and Lapthorn, A. J. (1996) Mol. Endocrinol. 10, 1147-1159[Abstract]
28. Dias, J. A., Lindau-Shepard, B., Hauer, C., and Auger, I. (1998) Biol. Reprod. 58, 1331-1336[Medline] [Order article via Infotrieve]
29. Moyle, W., Campbell, R., Rao, S., Ayad, N., Bernard, M., Han, Y., and Wang, Y. (1995) J. Biol. Chem. 270, 20020-20031[Abstract/Free Full Text]
30. Lustbader, J. W., Lobel, L., Wu, H., and Elliott, M. M. (1998) Recent Prog. Horm. Res. 53, 395-424[Medline] [Order article via Infotrieve]
31. Lapthorn, J. P., Harris, D. C., Littlejohn, A., Lustbader, J. W., Canfield, R. E., Machin, K. J., Morgan, F. J., and Isaacs, N. W. (1994) Nature 369, 455-461[CrossRef][Medline] [Order article via Infotrieve]
32. Wu, H., Lustbader, J. W., Liu, Y., Canfield, R. E., and Hendrickson, W. A. (1994) Structure (Lond.) 2, 545-558[Medline] [Order article via Infotrieve]
33. Song, Y. S., Ji, I., Beauchamp, J., Isaacs, N. W., and Ji, T. H. (2000) J. Biol. Chem. 276, 3426-3435[Abstract/Free Full Text]
34. Song, Y. S., Ji, I., Beauchamp, J., Isaacs, N. W., and Ji, T. H. (2000) J. Biol. Chem. 276, 3436-3442[Abstract/Free Full Text]
35. Jeoung, M., Phang, T., Song, Y. S., Ji, I., and Ji, T. H. (2000) J. Biol. Chem. 276, 3443-3450[Abstract/Free Full Text]
36. Hong, S., Phang, T., Ji, I., and Ji, T. H. (1998) J. Biol. Chem. 273, 13835-13840[Abstract/Free Full Text]
37. Phang, T., Kundu, G., Hong, S., Ji, I., and Ji, T. H. (1998) J. Biol. Chem. 273, 13841-13847[Abstract/Free Full Text]
38. Nakabayashi, K., Kudo, M., Kobilka, B., and Hsueh, A. J. (2000) J. Biol. Chem. 275, 30264-30271[Abstract/Free Full Text]
39. Ji, I., and Ji, T. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 5465-5469[Abstract]
40. Ji, I., and Ji, T. H. (1993) J. Biol. Chem. 268, 20851-20854[Abstract/Free Full Text]
41. Ji, I., and Ji, T. H. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 7167-7170[Abstract]
42. Ryu, K.-S., Gilchrist, R. L., Ji, I., Kim, S.-J., and Ji, T. H. (1996) J. Biol. Chem. 271, 7301-7304[Abstract/Free Full Text]
43. Tsai-Morris, C. H., Buczko, E., Wang, W., Xie, X. Z., and Dufau, M. L. (1991) J. Biol. Chem. 266, 11355-11359[Abstract/Free Full Text]
44. Angelova, K., Narayan, P., Simon, J. P., and Puett, D. (2000) Mol. Endocrinol. 14, 459-471[Abstract/Free Full Text]
45. Ji, I., and Ji, T. H. (1995) J. Biol. Chem. 270, 15970-15973[Abstract/Free Full Text]
46. Huhtaniemi, I., Jiang, M., Nilsson, C., and Pettersson, K. (1999) Mol. Cell. Endocrinol. 151, 89-94[CrossRef][Medline] [Order article via Infotrieve]
47. Struthers, M., Cheng, R., and Imperiali, B. (1996) Science 271, 342-346[Abstract]
48. Livnah, O., Stura, E., Johnson, D., Middleton, S., Mulcahy, L., Wrighton, N., Dower, W., Jolliffe, L., and Wilson, I. A. (1996) Science 271, 464-471[Abstract]
49. Cwirla, S., Balasubramanian, P., Duffin, D., Wagstrom, C., Gates, C., Singer, S., Davis, A., Tansik, R., Mattheakis, L., Boytos, C., Schatz, P., Baccanari, D., Wrighton, R., Barrett, R., and Dower, W. (1997) Science 276, 1696-1699[Abstract/Free Full Text]
50. Wrighton, N., Farrell, F., Chang, R., Kashyap, A., Barbone, F. P., Mulcahy, L. S., Johnson, D., Barrett, R., Jolliffe, L., and Dower, W. J. (1996) Science 273, 458-463[Abstract]
51. Roche, P., and Ryan, R. (1985) in Luteinizing Hormone Action and Receptors (Ascoli, A., ed) , pp. 17-56, CRC Press Inc., Boca Raton, FL
52. Janin, J., and Chothia, C. (1990) J. Biol. Chem. 265, 16027-16030[Free Full Text]
53. Chou, P., and Fasman, G. (1978) Adv. Enzymol. 47, 45-148[Medline] [Order article via Infotrieve]
54. Rothman, J., and Wielandd, F. (1996) Science 272, 227-234[Abstract]
55. Garnier, J., Osguthorpe, D., and Robson, B. (1978) J. Mol. Biol. 120, 97-120[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.